

EMA Clinical Trials Information System (CTIS) Information Day

17 October 2024
13:30 - 17:30 CET | VIRTUAL Event

| PROGRAMME COMMITTEE

Ana Zanoletty Perez

Head of Clinical Trials Transformation
Workstream
European Medicines Agency, EU

Francesca Scotti

CTIS Transparency lead
European Medicines Agency, EU

Marianne Lunzer

CTCG Chair
Assessor, Dept of Clinical Trials
AGES, AT

Peter Arlett

Head Data Analytics & Methods Task Force
European Medicines Agency, EU

Scott Feiner

Clinical Records Management
Strategic Clinical Operations
AbbVie, US

| FACULTY

Andrea Seidel-Glaetzer

Head of Project Management
Coordination Centre For Clinical Trials
Heidelberg (KKS), DE

Charalampos Drosos

CTIS business project officer
European Medicines Agency, EU

Fatima Pimentel

Director, Regulatory Consulting
Syneos Health, PT

Lora Killian

Transparency and Disclosure Lead
Pfizer, US

Noémie Manent

Principal Scientific Administrator
European Medicines Agency, EU

Polyana Bastos

Senior Legal Director
Johnson & Johnson, CH

| OVERVIEW

Since 31 January 2023, it has been mandatory for sponsors to submit all initial clinical trial applications via CTIS. In less than 7 months, from 31 January 2025 onwards, sponsors will need to comply with their obligations under the CTR and its Delegated Acts for all clinical trials conducted in the EU/EEA.

Furthermore, the revised transparency rules for the Clinical Trials Information System (CTIS) will become applicable on 18 June 2024, with the launch of a new version of the CTIS public portal.

The virtual event aims to support sponsors of clinical trials in proceeding with the transition to meet the deadline of 31 January 2025. Speakers will share detailed metrics on transitioned clinical trials. In addition, comprehensive guidance and practical examples regarding the following steps in transitioning trials will be presented.

Additionally, during the event representatives from EMA will provide an overview of the revised transparency rules as well as a demonstration of the new functionalities of CTIS new public portal.

Ample time is foreseen for Q&A. The faculty invites participants to submit related questions by 08 October 2024 latest to emaevents@diaglobal.org

| KEY TOPICS

- Transition period from the Clinical Trials Directive (2001/20/EC) to the Clinical Trial Regulation – regulatory and practical aspects
- Overview of the revised transparency rules
- Demonstration of the new functionalities of CTIS new public portal

| TARGET AUDIENCE

This EMA CTIS Virtual Information Day is aimed at CTIS users from:

- Pharmaceutical companies
- Small and medium sized enterprises (SMEs)
- Academic organisations
- Contract Research Organisations (CROs)
- Member State NCAs
- Ethics Committee Members



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

DIA

AGENDA | 17 October 2024 | 13:30 – 17:30 CET

13:30

WELCOME NOTE

Peter Arlett, Head Data Analytics & Methods Task Force, EMA, EU

SESSION 1: TRANSITION PERIODS FOR CLINICAL TRIALS FROM DIRECTIVE (2001/20/EC) TO REGULATION (536/2014)

SESSION CHAIRS: Ana Zanoletty Perez, EMA, EU & Scott Feiner, AbbVie, US

13:40

Transitioned Clinical Trials – Current Status and Key Metrics

Noémie Manent, EMA EU

14:00

Current Status about transitioning Clinical Trials and next steps

Marianne Lunzer, AGES, AT

14:15

Follow up on Transitioned Clinical Trials from Sponsors' Perspective

Scott Feiner, AbbVie, US

14:30

Follow up on Transitioned Clinical Trials from CROs' Perspective

Fatima Pimentel, Syneos Health, PT

14:45

Follow up on Transitioned Clinical Trials from Regulatory Perspective

Susanne Lerch, PEI, DE

Follow up on Transitioned Clinical Trials from Ethics Committee Perspective

Friederike Heckmann, AEKWL, DE

15:05

Q&A

15:30

BREAK

SESSION 2: TRANSPARENCY IN CLINICAL TRIALS

SESSION CHAIRS: Francesca Scotti, EMA, EU & Marianne Lunzer, AGES, AT

16:00

Overview of new Transparency Rules

Francesca Scotti, EMA, EU

Demonstration of the new Public Portal

Charalampos Drosos, EMA, EU

16:30

New Transparency rules –How to manage from a commercial sponsors' perspective

Polyana Bastos, J&J, CH & Lora Killian, Pfizer, US

New Transparency rules –How to manage from a non-commercial Sponsors' Perspective

Andrea Seidel-Glaetzer, KKS, DE

17:10

Q&A and wrap up

17:30

END OF THE INFORMATION DAY